ABBV vs RVTY
AbbVie vs Revvity — AI-powered side-by-side comparison
| Metric | ABBV | RVTY |
|---|
| AI Score |
69
|
75
|
| Price |
$249.34
|
$116.77
|
| P/E Ratio |
70.28×
|
55.64×
|
| ROE |
-129.2%
|
3.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
71.5%
|
52.1%
|
| Debt / Equity |
-11.93×
|
0.46×
|
| Dividend Yield |
2.7%
|
0.2%
|
| RSI (14) |
48.9
|
65.1
|
| Beta |
0.28
|
1.072
|
| Expected Upside |
—
|
+1.3%
|
AI Committee View
Current Innellis committee reasoning for ABBV versus RVTY.
RVTY leads by 6 points.
RVTY scores 75/100 (Buy) versus ABBV at 69/100 (Buy).
ABBV Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.20 across 84 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
RVTY Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is sector concentration is already high (hhi 2971.31). The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Stochastic RSI (92.1) confirms overbought conditions.
- Risk/reward is unfavorable: 28.5% downside vs 1.3% upside.